CRTI Exceptional Translational Research Award

The objective of MCC’s Cancer Research Translational Initiative (CRTI) Exceptional Translational Research Award. is to identify and fund outstanding translational research projects that will lead to sustainable high impact external funding. Translation is in any area of cancer research that applies or accelerates discovery into testing in clinical or population settings.

Grantees

2022

Pre-clinical testing of a B7-H3 targeting chimeric antigen receptor NK (B7-H3 CAR-iNK) construct in preparation for a first-in-human glioblastoma trial
Jianfang Ning, PhD, Department of Neurosurgery, Medical School

Jeffrey Miller, MD, Division of Hematology, Oncology and Transplantation, Medical School

Minnesota Annotated Genomics In Cancer (MAGIC) - An interactive multi-omics portal to study Masonic Cancer Center prostate cancer patients
Justin Hwang, PhD, Division of Hematology, Oncology and Transplantation, Medical School

Emmanuel Antonarakis, MD, Division of Hematology, Oncology and Transplantation, Medical School
Jinhua Wang, PhD, Institute for Health Informatics, Office of Academic Clinical Affairs

2021

RET Degraders for Treating Neuroendocrine Prostate Cancer
Justin Drake, PhD, Department of Pharmacology, Medical School

Daniel Harki, PhD, Medicinal Chemistry, College of Pharmacy

Engineered T cell therapy for poor prognosis cancers
Ingunn Stromnes, PhD, Department of Microbiology & Immunology, Medical School

Jeffrey Miller, MD, Division of Hematology, Oncology and Transplantation, Medical School